Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967075 | 0.86 | KMT2A (0.34) | P2RX7KMT2A | |
| SCHEMBL20913354 | 0.86 | P2RX7 (0.31) | P2RX7KMT2A | |
| SCHEMBL21967065 | 0.84 | MEN1 (0.34) | P2RX7KMT2A | |
| SCHEMBL20980140 | 0.84 | STK17B (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20959576 | 0.82 | PIN1 (0.46) | P2RX7 | |
| SCHEMBL20980139 | 0.81 | KMT2A (0.35) | KMT2A | |
| SCHEMBL20956327 | 0.76 | GNRHR (0.35) | P2RX7 | |
| SCHEMBL20913363 | 0.76 | — | — | |
| SCHEMBL22977614 | 0.74 | MAPK1 (0.34) | P2RX7 | |
| SCHEMBL20835356 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | HTR3E 4236/4885HTR3B 4048/4885HTR3A 4452/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | HTR3E 4236/4885HTR3B 4048/4885HTR3A 4452/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | HTR3E 3827/4885HTR3B 3762/4885HTR3A 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.